Nosa Med AB
The answer first
Does Nosa Med beat the market?
No, Nosa Med has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 28% of Nordic stocks
- Quality64
- Value19
- Trend40
No. 108 of 195 in healthcare
Max for seven days
Follow Nosa Med with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Nosa Med
Your first answer is free, no account needed.
Do you own Nosa Med, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Nosa Med and a few more. Free, no card.
Super Stock+46.4%In short
- Nosa Med has fallen 8.8% over the past year, including dividends.
- Overall, Nosa Med ranks better than 28% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 89.8%. The price is 98.7% below its peak now.
What do analysts think of Nosa Med?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 28% of Nordic stocks.
No. 108 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 100 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.04
- Asset turnoverSales divided by everything the company owns0.69
- Return on equityProfit divided by equity−10.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 102 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.2
- P/SPrice divided by sales3.2
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 91 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+3.7%
- 6 months−12.0%
- 9 months−21.7%
- 12 months−8.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Nosa Med
One fund we follow owns Nosa Med. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Nosa Med
Nosa Med AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 9 employees.
Nosa Plugs AB (publ), a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, Europe, North America, Oceania, and internationally. It offers NOSA smell training, a smell training medical device to improve the sense of smell for individuals with parosmia and hyposmia; NOSA odor control, which reduces bad odor; NOSA microbial control that reduces the exposure of viruses and bacteria by inhalation through the nose; NOSA Nozoil original, a moisturizing nasal spray for people suffering from dry nasal mucosa; and NOSA Cerevia, a nasal drug delivery platform for controlled administration of drugs.


See the full analysis of Nosa Med.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card